Precigen/$PGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ticker

$PGEN
Sector
Primary listing

Employees

143

Precigen Metrics

BasicAdvanced
$1.4B
-
-$0.43
1.87
-

What the Analysts think about Precigen

Analyst ratings (Buy, Hold, Sell) for Precigen stock.

Bulls say / Bears say

On August 15, 2025, the U.S. FDA gave full approval to Precigen’s immunotherapy Papzimeos (PRGN-2012)—the first approved treatment for recurrent respiratory papillomatosis—a major regulatory milestone that sent shares up 81% before the market opened (Reuters)
Early- and mid-stage clinical trial data for PRGN-2012 showed 51% of treated patients required no surgeries in the twelve months following treatment, pointing to strong and durable efficacy for a population with high unmet need (Reuters)
J.P. Morgan analysts estimate Papzimeos could achieve peak U.S. sales of about $250 million, signaling considerable revenue potential for this newly approved RRP therapy (Reuters)
Precigen’s first-quarter 2025 Form 10-Q reveals significant doubt about its ability to remain a going concern without either FDA approval of PRGN-2012 or new financing, highlighting acute liquidity risk (SEC)
As of March 31, 2025, Precigen reported $83.0 million in warrant liabilities—reflecting potentially substantial dilution from around 52.7 million warrants exercisable at $0.75—creating significant downside risk for shareholders (SEC)
In the first-quarter 2025 Form 10-Q, Precigen confirmed it shut down its ActoBio subsidiary and halted several clinical programs to preserve cash, increasing dependence on the binary outcome of PRGN-2012 and narrowing its pipeline (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Precigen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Precigen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PGEN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs